Newsroom - Page 4

A survey conducted by MaPS/Millward Brown Analytics, on behalf of Memorial Sloan Kettering Cancer Center, has identified multiple concerns of American consumers with cancer clinical trial participation, which could be responsible for the dismal 4% national enrollment rate in clinical trials.
What we're reading, May 24, 2016: Doubt grows about the stability of the Anthem-Cigna merger; use of e-cigarettes and vaping devices stalls in the US; and drugmakers are cautious about developing a Zika virus.
A phase 1 study in 225 patients diagnosed with breast cancer, non-small cell lung cancer, glioblastoma, melanoma, or colorectal cancer has concluded that abemaciclib, a selective inhibitor of the cell cycle regulators CDK4/6, has single-agent activity in specific tumor types.
For patients with private drug insurance plans, out-of-pocket expenses, not the timing of patient reimbursements, have a greater affect on medication adherence.
Finding diabetes and treating it early can prevent high healthcare costs in the long term, the authors day.
The updated label reflects research that shows how hard it is to consume key nutrients and maintain calorie limits in a diet overwhelmed by sugar. The label will be a legacy of First Lady Michelle Obama's focus on better nutrition to combat childhood obesity.
An Oklahoma-based non-profit hospital is the latest medical facility to sue pharmaceutical giant Genentech,accusing the company of shipping less than the labeled claim of the anticancer drug trastuzumab (Herceptin) in each multi-dose vial.
What we're reading, May 23, 2016: Oklahoma governor vetoes bill banning abortion; the FDA approved a new nutrition label highlighting sugar added; and 7 years after death panels, conversations on end-of-life planning are becoming more common.
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium
HF Compendium